Companion diagnostic for MTX5 and MTX3-targeting ADCs - Oncomatryx
Latest Information Update: 27 Jul 2016
At a glance
- Originator Oncomatryx
- Class Diagnostic agents; Monoclonal antibodies
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 27 Jul 2016 Preclinical trials in Cancer (Diagnosis) in Spain (unspecified route)